CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (IBRX), a leading immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access ...

Open-Source Hybrid Large Language Model Integrated System for Extraction of Breast Cancer Treatment Pathway From Free-Text Clinical Notes The diagnosis of chronic lymphocytic leukemia (CLL) is often ...

BN001, a signal seeking Phase II randomized trial, indicated that photon radiation dose intensification (75 Gy) did not ...

Credit: X4 Pharmaceuticals. The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 4WHILM trial. Findings showed mavorixafor was associated with statistically ...

Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved mavorixafor (Xolremdi) capsules as the first ...